Pediatric drug development can, in many ways, be described as a “Catch 22.” It is extremely challenging (both logistically and ethically) to enroll children in clinical trials, yet without a proper and approved clinical process, physicians are left with inaccurate dosing and therapeutic approaches for children. Modeling and simulation methods, including population PK modeling, are reshaping the pharmaceutical industry’s approach to pediatric drug development. In this webinar, Dr. Nathalie Gosselin presented a case study wherein Certara Strategic Consulting scientists leveraged population PK modeling and simulation to help optimize dosing of an antibiotic for infants.
About Our Speaker
Nathalie Gosselin, Principal Scientist, Certara. Nathalie Gosselin earned a Master’s degree in Applied Mathematics and a PhD in Public Health–Environmental Toxicology from the University of Montreal. Since joining Certara in 2008, Dr. Gosselin has performed PK, PK/PD and exposure-response analyses, reporting, and modeling and simulation projects in early and late stage clinical research. As a Principal Scientist, Dr. Gosselin currently leads a team of 3 scientists and has published 15 peer-reviewed papers and 40 conference abstracts.
Pediatric drug development can, in many ways, be described as a “Catch 22.” It is extremely challenging (both logistically and ethically) to enroll children in clinical trials, yet without a proper and approved clinical process, physicians are left with inaccurate dosing and therapeutic approaches for children. Modeling and simulation methods, including population PK modeling, are reshaping the pharmaceutical industry’s approach to pediatric drug development. In this webinar, Dr. Nathalie Gosselin presented a case study wherein Certara Strategic Consulting scientists leveraged population PK modeling and simulation to help optimize dosing of an antibiotic for infants.